Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Don't Floss, You Lose - (ATRX) To the RESCUE. -- Ignore unavailable to you. Want to Upgrade?

To: Fred McCutcheon who wrote (165)	7/19/2000 2:21:55 PM
From: Fred McCutcheon	Read Replies (1) \| Respond to of 182

Wednesday July 19, 1:17 pm Eastern Time Company Press Release SOURCE: Atrix Laboratories Rapid Enrollment of Atrix Clinical Studies FORT COLLINS, Colo., July 19 /PRNewswire/ -- Atrix Laboratories (Nasdaq: ATRX - news) announced today that enrollment was completed sooner than anticipated for Atrisone(TM), dapsone topical gel, in Phase II clinical trials for moderate to severe acne. Additionally, Atrix has began enrollment for the Phase III 90-day sustained release Leuprogel(TM), leuprolide acetate, clinical trial for the treatment of advanced prostate cancer. ``We are pleased that we were able to move Atrisone(TM) towards conclusion sooner than scheduled,'' said Dr. Steve Garrett, vice president of clinical development. ``The Atrisone(TM) Phase II clinical trial is a multi-center, double blind dose ranging study expected to be completed mid-October. We believe this Phase II study will determine the most effective dose for use in the Phase III study beginning early next year. '' The Leuprogel(TM) 90-day product is designed to deliver leuprolide acetate over a three month period in order to reduce testosterone level for the treatment of prostate cancer. The study is multi-center and enrollment is expected to be complete by late this year. ``The 90-day Leuprogel(TM) product extends the market opportunity for Atrix in the area of prostate cancer,'' said David Bethune, chairman and chief executive officer. ``Atrix 90-day product will follow closely behind our 30-day product which is also in Phase III and completely enrolled. This will give clinicians the range of dosing opportunities that they have come to expect.'' biz.yahoo.com Fred mcCutcheon